CHEPLAPHARM Aligns Management Board for Strategic Growth

Cheplapharm, a global leader in acquiring pharmaceutical products, is realigning its Management Board to focus on its next growth phase. Following a period of transformation, the company aims to drive growth through strategic transactions and partnerships with major pharmaceutical firms.

Dr. Keyarasch Parssanedjad, current CFO, will transition to the role of Chief Business & Strategy Officer (CBSO) on June 1, 2026. He will oversee strategy development, focusing on strategic transactions and innovative partnerships. The Human Resources division will also remain under his purview.

Martin Krämer joins as the new CFO, strengthening Cheplapharm's financial organization. With extensive finance experience in the chemical industry, Krämer will manage Finance, Internal Audit & Risk Management, and Treasury & Investor Relations.

These appointments are aligned with Cheplapharm’s strategic priorities, focusing on growth and value creation through systematic management enhancement.